Valuation
- Market cap
- 164,839,000
- Revenue TTM
- $0
- Net income TTM
- $-89,660,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 603,800
- Avg volume
- 893,238
- Day's range
- $2.39 – $2.65
- Shares out
- 69,260,000
- Stochastic %K
- 93%
- Beta
- 2.01
- Analysts
- Strong Sell
- Price target
- $10.19
Company profile
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystr...
Show more
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 797 0979
- Website
- https://www.pepgen.com
- Address
- 321 Harrison Avenue, 8th Floor, Boston, United States
Latest news
No headlines yet.
